Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: A critical appraisal

British Journal of Dermatology

Volumn 167, Issue 4, 2012, Pages 710-713

  Spuls, Ph I ^a   Hooft, L ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRODALUMAB; GLUCOCORTICOID; IXEKIZUMAB; PLACEBO;

ARTHRALGIA; BODY SURFACE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; KIDNEY COLIC; NEUTROPENIA; NOTE; PAIN ASSESSMENT; PERIPHERAL EDEMA; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; REMISSION; SHORT FORM 36; SYSTEMIC THERAPY; TREATMENT OUTCOME; URTICARIA; VISUAL ANALOG SCALE;

EID: 84867021009     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12025     Document Type: Note

References (12)

1. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T-cell population that induces autoimmune inflammation. J Exp Med 2005; 201: 233-40.
2. Fitch E, Harper E, Skorcheva I, et al. Pathophysiology of psoriasis: recent advances on IL23 and Th17 cytokines. Curr Rheumatol Rep 2007; 9: 461-7.
3. Waisman A,. To be 17 again-anti-interleukin-17 treatment for psoriasis. N Engl J Med 2012; 366: 1251-2.
4. Raychaudhuri SP,. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol 2012 Feb 24 [Epub ahead of print].
5. Genovese MC, van den Bosch F, Roberson SA, et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis. A phase I randomized, double-blind, placebo-controlled, proof of concept study. Arthritis Rheum 2010; 62: 929-39.
6. Hueber W, Patel DD, Drya T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis and uveitis. Sci Transl Med 2010; 2: ra72.
7. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17- receptor antibody for psoriasis. N Engl J Med 2012; 366: 1181-9.
8. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366: 1190-9.
9. Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340: c332.
10. Schmitt J, Spuls P, Boers M, et al. Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. Core outcome measures for atopic eczema research. Allergy 2012; 67: 1111-7.
11. Schmitt J, Spuls P, Williams H,. The Harmonizing Outcome Measures for Eczema (HOME) initiative. BMJ 2010; 340: c869.
12. Proceedings of OMERACT 10, the International Consensus Conference on Outcome Measures in Rheumatology Clinical Trials. May 4-8, 2010. Kota Kinabalu, Borneo. J Rheumatol 2011; 38: 1448-518.